We set up in 2023 with the aim to develop and commercialize a pharmaceutical solution in to related products.
The aim is to seek out products to treat Deep Wounds – physical or cause by disease – using no or limited synthetic chemicals and to use on mostly natural materials.
The company is formed as a private limited company and setup the process for commercializing the research and development work carried out earlier in independent labs.
Sourcing materials entirely from within the country the product were developed in few types
of healing materials.
These include as healing powder, cream, paste and as wound covering sheets. Additional products with cosmetic uses are also bring developed in lab scale.
We would be conducting clinical studies for all these products and to obtain the licences to manufacture and market.
At Inger Therapeutics, we are passionate about discovering such high affinity ligands called Suprabodies for therapeutic and diagnostic applications. Suprabodies are ligands that are synthetic and low molecular weight discovered using a stringent and robust Suprabody selection methodology. Suprabody and its generation methodology addresses the limitations of the existing technologies and still retains its strengths. The innovative elements in the suprabody include: (i) completely synthetic scaffold with a possibility to include unnatural moieties (ii) multiple loops aids in cooperativity (iii) introduce shuffling in the selection process that helps in discovering the best binders via multiple rounds of selection. Eventually, these advantages reflect in smaller synthetic products that are scalable and favourable in tissue penetration.
The prototype was shown and published in high impact factor journal Nature Chemistry
